23EL-822 On-Demand eCast: Cell Analytics 101

Live Program Date: Wednesday, April 12, 2023
Program Number: 23EL-822

Educational Track: Scientific
Topic: Cellular Therapy
Intended Audience: Directors, Immunohematology Reference Labs (IRL’s), Laboratory Staff, Managers/Supervisors, Medical Directors, Physicians, Research Scientists, Residents/Fellows, Scientists, Students (MD, MT, SBB), Technologists
Teaching Level: Basic, Intermediate

Faculty
(titles and affiliations at the time of the live program)
Director: Indira Guleria, PhD Diplomate (ABHI), CABP(H), Director, Histocompatibility and Immunogenetics (HLA), Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
Moderator: Andrew Fesnak, MD, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Speakers: Indira Guleria, PhD Diplomate (ABHI), CABP(H), Director, Histocompatibility and Immunogenetics (HLA), Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Asawari Bapat, DPB, PGDHHM, CABP, Department of Quality and Regulatory Affairs, Infohealth FZE and Questar Enterprises, Dubai, United Arab Emirates

Program Description
A broad variety of cell types are being utilized as therapeutics in the cellular therapy field. The most commonly used cellular therapy products (CTP) are stem cells and T cells. Full characterization of CTP requires that cell analytics such as - cell identity, cell viability, cell purity and cell potency be assessed for the product to be safe and effective. The program faculty will describe the current characterization strategies and analytical tools that cellular therapy laboratories and manufacturers use to measure identity, viability, purity and potency of CTPs along with the benefits and limitations of each of these methodologies.

Discussion on product release criteria as to what CTP characterization should be obtained before a cellular therapy product may leave the control of the collection or processing facility will also be part of this program. This includes assessment of all the cell attributes as mentioned above and in addition includes sterility testing and stability testing. This program will also cover future opportunities and techniques on the horizon for more in-depth and automated monitoring of cell analytics.

Learning Objectives
After participating in this educational activity, participants should be able to:

• Describe the significance and basic techniques used for the characterization of cells used in Cellular Therapy Products (CTPs) and to recognize the scope, advantages, and limitations of each technique.
• Identify the requirements that must be met before a CTP is released for infusion.
• Discuss new methodologies and platforms on the horizon in the Cellular Therapy (CT) cell analytics field.

How to Claim Continuing Education Credit

• Single Viewers: if you registered as a single viewer, complete the evaluation found on the "CE Information" tab after watching the video. By submitting the evaluation, you are attesting to watching the presentation in its entirety.

• Group Viewers: This is applicable for groups/facilities that purchased Group Viewing access for this program (registration will be verified prior to processing a group viewing attendance log). Group Viewing Coordinators should submit the attendance log to eLearning@aabb.org within 72 hours of the completion/viewing date. Once AABB receives an attendance log, each participant on the attendance log will be granted access as a single viewer to this program and will be required to complete the evaluation in order to claim continuing education credit. Each participant will be required to have an AABB account in order to access this program/platform. If a participant does not have an account, he/she can create one using the same email address provided on the attendance log.